Susquehanna International Group’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Susquehanna International Group’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,069	Closed	-$5.62K	–	13787
2024 Q4	$5.62K	Sell	1,069 -530	-33%	-$3.48K	﹤0.01%	12003
2024 Q3	$22.9K	Buy	+1,599	New	+$21.9K	﹤0.01%	11597
2023 Q2	–	Sell	-1,356	Closed	-$28.2K	–	13374
2023 Q1	$28.2K	Buy	+1,356	New	+$30.4K	﹤0.01%	11937
2022 Q3	–	Sell	-878	Closed	-$23K	–	14312
2022 Q2	$23K	Buy	878 +223	+34%	+$9.92K	﹤0.01%	12332
2022 Q1	$52K	Buy	+655	New	+$80.9K	﹤0.01%	12298
2021 Q2	–	Sell	-543	Closed	-$210K	–	13404
2021 Q1	$210K	Buy	+543	New	+$219K	﹤0.01%	11346

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's VINC Position: Q1 2025 in Review

Susquehanna International Group sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 1,069 shares — an estimated $5.62K sold.

Susquehanna International Group first reported a position in VINC in Q1 2021 and held it in 6 quarters. The position peaked at $210K in Q1 2021. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

Susquehanna International Group reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Susquehanna International Group sold 1,069 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $5.62K.
Susquehanna International Group first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Susquehanna International Group's Vincerx Pharma, Inc. Common Stock position peaked at $210K in Q1 2021.
14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.